JP2001503266A5 - - Google Patents

Download PDF

Info

Publication number
JP2001503266A5
JP2001503266A5 JP1998520528A JP52052898A JP2001503266A5 JP 2001503266 A5 JP2001503266 A5 JP 2001503266A5 JP 1998520528 A JP1998520528 A JP 1998520528A JP 52052898 A JP52052898 A JP 52052898A JP 2001503266 A5 JP2001503266 A5 JP 2001503266A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP1998520528A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001503266A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1997/018703 external-priority patent/WO1998018926A1/en
Publication of JP2001503266A publication Critical patent/JP2001503266A/ja
Publication of JP2001503266A5 publication Critical patent/JP2001503266A5/ja
Abandoned legal-status Critical Current

Links

JP52052898A 1996-10-25 1997-10-23 環状に並べ替えたエリスロポイエチン受容体アゴニスト Abandoned JP2001503266A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3404496P 1996-10-25 1996-10-25
US60/034,044 1996-10-25
PCT/US1997/018703 WO1998018926A1 (en) 1996-10-25 1997-10-23 Circularly permuted erythropoietin receptor agonists

Publications (2)

Publication Number Publication Date
JP2001503266A JP2001503266A (ja) 2001-03-13
JP2001503266A5 true JP2001503266A5 (https=) 2005-05-12

Family

ID=21873960

Family Applications (1)

Application Number Title Priority Date Filing Date
JP52052898A Abandoned JP2001503266A (ja) 1996-10-25 1997-10-23 環状に並べ替えたエリスロポイエチン受容体アゴニスト

Country Status (13)

Country Link
US (1) US20060172932A1 (https=)
EP (1) EP0939816A1 (https=)
JP (1) JP2001503266A (https=)
KR (1) KR20000052807A (https=)
CN (1) CN1234073A (https=)
AU (1) AU721196B2 (https=)
BR (1) BR9712675A (https=)
CA (1) CA2268001A1 (https=)
CZ (1) CZ130199A3 (https=)
NO (1) NO991906D0 (https=)
NZ (1) NZ334546A (https=)
PL (1) PL189756B1 (https=)
WO (1) WO1998018926A1 (https=)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7309687B1 (en) 1999-04-13 2007-12-18 The Kenneth S. Warren Institute, Inc. Methods for treatment and prevention of neuromuscular and muscular conditions by peripherally administered erythropoietin
US7345019B1 (en) 1999-04-13 2008-03-18 The Kenneth S. Warren Institute, Inc. Modulation of excitable tissue function by peripherally administered erythropoietin
US8236561B2 (en) 1999-04-15 2012-08-07 Crucell Holland B.V. Efficient production of IgA in recombinant mammalian cells
US7297680B2 (en) 1999-04-15 2007-11-20 Crucell Holland B.V. Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
US7604960B2 (en) 1999-04-15 2009-10-20 Crucell Holland B.V. Transient protein expression methods
US6855544B1 (en) 1999-04-15 2005-02-15 Crucell Holland B.V. Recombinant protein production in a human cell
US7192759B1 (en) 1999-11-26 2007-03-20 Crucell Holland B.V. Production of vaccines
US7527961B2 (en) 1999-11-26 2009-05-05 Crucell Holland B.V. Production of vaccines
US7521220B2 (en) 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
PA8536201A1 (es) 2000-12-29 2002-08-29 Kenneth S Warren Inst Inc Protección y mejoramiento de células, tejidos y órganos que responden a la eritropoyetina
US6531121B2 (en) 2000-12-29 2003-03-11 The Kenneth S. Warren Institute, Inc. Protection and enhancement of erythropoietin-responsive cells, tissues and organs
PT1465987E (pt) 2001-12-07 2008-04-15 Crucell Holland Bv Produção de vírus, isolados virais e vacinas
WO2004099396A1 (en) 2003-05-09 2004-11-18 Crucell Holland B.V. Cultures of e1-immortalized cells and processes for culturing the same to increase product yields therefrom
CA2595676A1 (en) * 2005-01-25 2006-08-03 Apollo Life Sciences Limited Molecules and chimeric molecules thereof
ES2649983T3 (es) 2005-11-23 2018-01-16 Acceleron Pharma, Inc. Antagonistas de activina-ActRIIa en su uso para promover el crecimiento óseo
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
WO2007060213A2 (en) * 2005-11-24 2007-05-31 Laboratoires Serono S.A. Erythropoietin polypeptides and uses thereof
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
MX2009008222A (es) 2007-02-01 2009-10-12 Acceleron Pharma Inc Antagonistas de activina-actriia y usos para tratar o prevenir cancer de mama.
TW201803890A (zh) 2007-02-02 2018-02-01 艾瑟勒朗法瑪公司 衍生自ActRIIB的變體與其用途
EA018221B1 (ru) 2007-02-09 2013-06-28 Акселерон Фарма Инк. АНТАГОНИСТЫ АКТИВИНА-ActRIIa И ПРИМЕНЕНИЕ ДЛЯ СТИМУЛЯЦИИ РОСТА КОСТИ У БОЛЬНЫХ РАКОМ
CN101861161B (zh) 2007-09-18 2017-04-19 阿塞勒隆制药公司 活化素‑actriia拮抗剂和减少或抑制fsh分泌的用途
TW201803586A (zh) 2008-08-14 2018-02-01 艾瑟勒朗法瑪公司 使用gdf阱以增加紅血球水平
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
KR20120049214A (ko) 2009-06-08 2012-05-16 악셀레론 파마 인코포레이티드 발열성 지방세포를 증가시키는 방법
KR20180026795A (ko) 2009-06-12 2018-03-13 악셀레론 파마 인코포레이티드 절두된 ActRIIB-FC 융합 단백질
EP3332796A1 (en) 2009-11-17 2018-06-13 Acceleron Pharma Inc. Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
AU2011326586A1 (en) 2010-11-08 2013-05-30 Acceleron Pharma, Inc. ActRIIA binding agents and uses thereof
US9156897B2 (en) 2012-06-08 2015-10-13 Alkermes, Inc. Fusion polypeptides comprising an active protein linked to a mucin-domain polypeptide
US10195249B2 (en) 2012-11-02 2019-02-05 Celgene Corporation Activin-ActRII antagonists and uses for treating bone and other disorders
CN114699529A (zh) 2014-06-13 2022-07-05 阿塞勒隆制药公司 用于治疗溃疡的方法和组合物
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
JP2018501307A (ja) 2014-12-03 2018-01-18 セルジーン コーポレイション アクチビン−ActRIIアンタゴニスト及び貧血を治療するための使用
CN110144010B9 (zh) 2018-02-14 2021-01-05 上海洛启生物医药技术有限公司 阻断型pd-l1驼源单域抗体及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4751180A (en) * 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
WO1992006116A1 (en) * 1990-09-28 1992-04-16 Ortho Pharmaceutical Corporation Hybrid growth factors
US5738849A (en) * 1992-11-24 1998-04-14 G. D. Searle & Co. Interleukin-3 (IL-3) variant fusion proteins, their recombinant production, and therapeutic compositions comprising them
US5635599A (en) * 1994-04-08 1997-06-03 The United States Of America As Represented By The Department Of Health And Human Services Fusion proteins comprising circularly permuted ligands

Similar Documents

Publication Publication Date Title
JP2001507604A5 (https=)
JP2000502280A5 (https=)
JP2000515657A5 (https=)
JP2000501771A5 (https=)
JP2000501599A5 (https=)
JP2000509213A5 (https=)
JP2000501018A5 (https=)
JP2001502318A5 (https=)
JP2000501324A5 (https=)
JP2000510667A5 (https=)
JP2000502472A5 (https=)
JP2000501338A5 (https=)
JP2000501825A5 (https=)
JP2000502485A5 (https=)
JP2000502425A5 (https=)
JP2000502568A5 (https=)
JP2000501774A5 (https=)
JP2000502570A5 (https=)
JP2000517174A5 (https=)
JP2000501876A5 (https=)
JP2000517281A5 (https=)
JP2001503266A5 (https=)
JP2000501744A5 (https=)
JP2000501229A5 (https=)
JP2000502316A5 (https=)